SANOFI Sanofi India Q3 FY26 results (Oct–Dec 2025) and concall
Sanofi India reported a year of transformation in 2025, leading to flat domestic sales but a 1% increase in full-year profit before tax and 4% in profit after tax. The insulin portfolio, particularly Lantus and Toujeo, demonstrated strong growth, with overall insulin sales up 6% for the year and 11% in Q4. However, partnership sales experienced volatility and a decline, while exports also dropped significantly. The company is focusing on maximizing its current diabetes portfolio and expects continued growth, potentially double-digit, once transformation impacts stabilize.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 18.4%, net profit down 31.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 524 | 515 | 536 | 406 | 475 −9% | 420 −18% |
| EBITDA | 120 | 118 | 172 | 95 | 134 +12% | 90 −24% |
| Net profit | 82 | 91 | 120 | 70 | 76 −7% | 62 −32% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
